New calculator reveals whether you should really worry about statin side effects

The research, published in The Lancet Digital Health, found that more than 98% of people identified by their general practitioners as eligible for statin therapy were at low predicted risk of developing a serious muscle disorder over the following 10 years. The findings suggest that fears about severe muscle related side effects may be overstated for most people who could benefit from treatment.

New Tool Aims To Personalize Statin Decisions

The researchers also uncovered a significant treatment gap. More than 60% of people who were eligible to take statins were not using them, even though some faced a high risk of heart attack or stroke. The team believes the new calculator could improve conversations between patients and clinicians by providing personalized estimates of risk instead of relying on general statistics or broad concerns about side effects.

The calculator, available through the Oxford University Innovation software store, is based on a clinical prediction model developed and tested using anonymized health records from more than 5.6 million people registered with GP practices across England. Researchers built the model using data from more than 1.7 million people and then validated its accuracy with records from another 3.9 million.

How the Statin Risk Calculator Works

The model analyzes 22 routinely collected health factors to estimate the likelihood of developing a serious muscle disorder over one, five, and 10 years. These factors include age, sex, ethnicity, body mass index, smoking status, existing medical conditions, previous muscle problems, vitamin D deficiency, medication use, and whether a person has been prescribed statins.

Researchers expect the calculator to be used alongside cardiovascular risk assessment tools such as QRISK. Together, these tools could help doctors and patients weigh both the benefits of lowering the risk of heart attacks and strokes and the potential risk of serious muscle complications when deciding whether statin treatment is appropriate.

Putting Statin Side Effects Into Perspective

Statins are among the most commonly prescribed medications for preventing cardiovascular disease. However, worries about muscle related side effects often discourage people from starting treatment or lead them to stop taking the medication, even when the potential benefits are substantial.

The researchers emphasized that their work focuses only on serious muscle disorders that result in hospital admission or death, not the milder muscle aches and pains that some people experience. Previous research has shown that many mild muscle symptoms reported during statin treatment are not actually caused by statins and should not prevent patients from beginning therapy. Although serious muscle disorders are much less common, understanding the possibility of these rare events remains important when balancing the risks and benefits of treatment.

Dr. Ting Cai, Research Fellow in the Nuffield Department of Primary Care Health Sciences, University of Oxford, and lead author of the study, said:

"Serious muscle disorders are one of the most widely discussed concerns about statins, but our findings suggest that the risk is very low for the vast majority of people who may benefit from treatment. Understanding a person's risk can help put those concerns into perspective, support more informed treatment decisions and provide reassurance. For the small number of people at higher risk, it gives clinicians a clearer basis for discussing monitoring, checks or alternative treatment options."

Personalized Risk Could Improve Treatment Decisions

Professor James Sheppard, Professor of Primary Care Research at the University of Oxford and a senior author of the study, said:

"Treatment decisions are often based on estimates of a person's future cardiovascular risk, but much less information is available about their individual risk of adverse outcomes. This research helps address that gap by providing a way to estimate a person's risk of serious muscle disorders alongside their cardiovascular risk. Bringing those two pieces of information together could support more personalized and better-informed decisions about statin treatment."

Professor Constantinos Koshiaris, Assistant Professor of Medical Statistics at the University of Nicosia Medical School and a senior author of the study, said:

"Clinical decisions are often based on estimates of potential benefit, but understanding potential harms is equally important. This model provides a way to quantify that risk at an individual level, helping support more balanced discussion about treatment options."

By offering personalized estimates of both potential benefits and risks, the researchers hope the calculator will help patients and healthcare providers make more confident, evidence based decisions about statin treatment and long term cardiovascular disease prevention.

The online calculator based on the model will be available through the Oxford University Innovation software store as the STRATIFY-StatinMD Risk Calculator -- Academic use.

The study was funded by a British Heart Foundation PhD Scholarship (ref: FS/19/13/34235). James Sheppard and Constantinos Koshiaris were supported by the Wellcome Trust and the Royal Society (Sir Henry Dale Fellowship, ref: 211182/Z/18/Z) and the National Institute for Health and Care Research (NIHR) School for Primary Care Research. Richard McManus was supported by an NIHR Senior Investigator award. Richard Hobbs was partially supported by the NIHR Applied Research Collaboration Oxford and Thames Valley.